Skip to main content

Table 1 Clinical trials on MSC application in AKI

From: Novel preconditioning strategies for enhancing the migratory ability of mesenchymal stem cells in acute kidney injury

Aim of study

Enrollment

Phase

Status

ClinicalTrials.gov identifier

To determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant AKI after undergoing on-pump cardiac surgery

18

Phase I

Completed

NCT00733876

To determine the safety and efficacy of allogeneic human MSCs in reducing the time to recover from AKI after cardiac surgery

156

Phase II

Terminated

NCT01602328

To assess the safety and tolerability of SBI-101, a biologic/device combination product using allogeneic human MSCs in subjects with AKI

24

Phase I

Recruiting

NCT03015623

  1. AKI acute kidney injury, MSC mesenchymal stem cell